Cargando…

Comparison of Treatment Goals between Users of Biological and Non-Biological Therapies for Treatment of Psoriasis in Japan

Background: Previously, our cross-sectional observational study in Japan revealed high (68%) discordance within treatment goals between psoriasis patients and their physicians. Objective: This secondary analysis aimed to determine whether patient and physician users of biologics have higher treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okubo, Yukari, Tang, Ann Chuo, Inoue, Sachie, Torisu-Itakura, Hitoe, Ohtsuki, Mamitaro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8709044/ https://www.ncbi.nlm.nih.gov/pubmed/34945027 http://dx.doi.org/10.3390/jcm10245732

Ejemplares similares

Analysis of treatment goal alignment between Japanese psoriasis patients and their paired treating physicians
por: Okubo, Y., et al.
Publicado: (2017)

Ixekizumab 80 mg Every 2 Weeks Treatment Beyond Week 12 for Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis
por: Morita, Akimichi, et al.
Publicado: (2021)

Biologics for Psoriasis during the COVID-19 Pandemic
por: Kamiya, Koji, et al.
Publicado: (2021)

Efficacy and safety of ixekizumab treatment in Japanese patients with moderate‐to‐severe plaque psoriasis: Subgroup analysis of a placebo‐controlled, phase 3 study (UNCOVER‐1)
por: Imafuku, Shinichi, et al.
Publicado: (2017)

Population pharmacokinetic and exposure–response analysis of apremilast in Japanese subjects with moderate to severe psoriasis
por: Okubo, Yukari, et al.
Publicado: (2021)

Pharmacodynamic analysis of apremilast in Japanese patients with moderate to severe psoriasis: Results from a phase 2b randomized trial
por: Imafuku, Shinichi, et al.
Publicado: (2020)

Patient preference for biologic treatments of psoriasis in Japan
por: Tada, Yayoi, et al.
Publicado: (2019)

Epidemiological survey of patients with pustular psoriasis in the Japanese Society for Psoriasis Research from 2017 to 2020
por: Kamiya, Koji, et al.
Publicado: (2022)

Long‐term efficacy and safety of secukinumab in Japanese patients with moderate to severe plaque psoriasis: 3‐year results of a double‐blind extension study
por: Okubo, Yukari, et al.
Publicado: (2019)

Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial
por: Ohtsuki, Mamitaro, et al.
Publicado: (2017)

Relationship Between Rapid Skin Clearance and Quality of Life Benefit: Post Hoc Analysis of Japanese Patients with Moderate-to-Severe Psoriasis Treated with Ixekizumab (UNCOVER-J)
por: Honma, Masaru, et al.
Publicado: (2020)

Dermatologist and Patient Perceptions of Treatment Success in Alopecia Areata and Evaluation of Clinical Outcome Assessments in Japan
por: Macey, Jake, et al.
Publicado: (2021)

Drug Survival of Tumor Necrosis Factor-Alpha Inhibitors and Switched Subsequent Biologic Agents in Patients with Psoriasis: A Retrospective Study
por: Kishimoto, Megumi, et al.
Publicado: (2023)

Epidemiological survey of the psoriasis patients in the Japanese Society for Psoriasis Research from 2013 to 2018
por: Kamiya, Koji, et al.
Publicado: (2021)

Epidemiological survey of patients with psoriatic arthritis in the Japanese Society for Psoriasis Research from 2017 to 2020
por: Kamiya, Koji, et al.
Publicado: (2022)

Safety and effectiveness of secukinumab in psoriasis vulgaris and psoriatic arthritis: Real‐world evidence in Japan
por: Fujita, Hideki, et al.
Publicado: (2020)

Risk Factors for the Development of Psoriasis
por: Kamiya, Koji, et al.
Publicado: (2019)

Co‐expression of Thymidine Phosphorylase and Heme Oxygenase‐1 in Macrophages in Human Malignant Vertical Growth Melanomas
por: Torisu‐Itakura, Hitoe, et al.
Publicado: (2000)

Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study
por: Asahina, Akihiko, et al.
Publicado: (2023)

Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64‐week phase 3 study (reSURFACE 1)
por: Igarashi, Atsuyuki, et al.
Publicado: (2021)

Safety and efficacy of adalimumab treatment in Japanese patients with psoriasis: Results of SALSA study
por: Asahina, Akihiko, et al.
Publicado: (2016)

Long‐term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5‐year extension of a phase 3 study (reSURFACE 1)
por: Imafuku, Shinichi, et al.
Publicado: (2021)

Assessment of serum biomarkers in patients with plaque psoriasis on secukinumab
por: Morita, Akimichi, et al.
Publicado: (2020)

Predicting treatment success with biologics in psoriasis
por: van den Reek, J.M.P.A.
Publicado: (2019)

Biologic Treatments of Psoriasis: An Update for the Clinician
por: Brownstone, Nicholas D, et al.
Publicado: (2021)

Neurological Complications of Biological Treatment of Psoriasis
por: Ożóg, Mateusz Kamil, et al.
Publicado: (2022)

Persistence and Adherence to Biologics in Patients with Psoriasis in Taiwan: A New Biologics User Cohort Study
por: Huang, Yu-Huei, et al.
Publicado: (2022)

Pooled Safety Analysis of Baricitinib in Adult Participants with Atopic Dermatitis in the Japanese Subpopulation from Six Randomized Clinical Trials
por: Katoh, Norito, et al.
Publicado: (2022)

Long‐term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open‐label, phase 3 study (UNCOVER‐J)
por: Okubo, Y., et al.
Publicado: (2018)

Advancements in the Treatment of Psoriasis: Role of Biologic Agents
por: Rich, Sheldon J., et al.
Publicado: (2004)

Tacrolimus ointment for the treatment of adult and pediatric atopic dermatitis: Review on safety and benefits
por: Ohtsuki, Mamitaro, et al.
Publicado: (2018)

Guselkumab, an anti‐interleukin‐23 monoclonal antibody, for the treatment of moderate to severe plaque‐type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double‐blind, placebo‐controlled study
por: Ohtsuki, Mamitaro, et al.
Publicado: (2018)

Safety, efficacy, and drug survival of the infliximab biosimilar CT‐P13 in post‐marketing surveillance of Japanese patients with psoriasis
por: Morita, Akimichi, et al.
Publicado: (2022)

Biological markers in the etiology of psoriasis: Targeted treatment options
por: de Felice, Catia, et al.
Publicado: (2007)

Emerging treatments in the management of psoriasis: biological targeting with ustekinumab
por: Papoutsaki, Marina, et al.
Publicado: (2009)

Quo vadis, biological treatment for psoriasis and psoriatic arthritis?
por: Olszewska, Barbara, et al.
Publicado: (2018)

Biologic Treatment Options for Pediatric Psoriasis and Atopic Dermatitis
por: Cline, Abigail, et al.
Publicado: (2019)

Patient Preference for Biologic Treatments of Psoriasis in the Chinese Setting
por: Lang, Yitian, et al.
Publicado: (2022)

Treatment Options and Goals for Patients with Generalized Pustular Psoriasis
por: Krueger, James, et al.
Publicado: (2022)

Immunotherapy for the Treatment of Squamous Cell Carcinoma: Potential Benefits and Challenges
por: Ansary, Tuba M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5a5atlm1tnss8haijsnc7f05oe